New hope for hard-to-treat lung cancer: targeted drug combo enters key trial
NCT ID NCT07336732
First seen Jan 19, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This study tests a new drug called andamertinib, alone or with chemotherapy, for people with advanced lung cancer that has certain rare gene changes (atypical EGFR mutations). About 40 participants who have not had prior treatment will be randomly assigned to receive the drug, the drug plus chemo, or chemo alone. The goal is to see if the drug shrinks tumors and is safe, with the hope of offering a more effective treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.